Asterion and Genzyme in protein research and option agreement
This article was originally published in Scrip
The UK “third generation” biotech firm Asterion has signed a research and option agreement with Genzyme to develop a long-acting form of an undisclosed non-cytokine protein. Genzyme will gain access to Asterion’s intellectual property surrounding a specific protein target and will research the creation of a long-acting and potent version of it. Nomura Code analysts say that although the project is at an early stage, it "signals a further endorsement" of Asterion’s technology platform. The Asterion Fusion Technology provides more easily administered versions of largely protein-based drugs. Its lead candidates, long-acting growth hormone proteins, are expected to enter clinical trials in 2009-10. They are being developed with Ipsen for conditions including short stature and acromegaly, a disorder caused by excess production of growth hormone. Asterion, a spin-out of the University of Sheffield, is a portfolio company of Fusion IP (Scrip Online, March 27th, 2008). Fusion IP has the rights to the IP generated by Sheffield and Cardiff Universities, giving it an R&D spend of around £167 million, says Nomura. With this research spend and a portfolio of more than 25 companies, the analyst firm believes Fusion IP is undervalued.
You may also be interested in...
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.